Animals
Anthracyclines
/ administration & dosage
Antineoplastic Agents
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ toxicity
Bortezomib
/ administration & dosage
Cardiotoxicity
/ etiology
Daunorubicin
/ administration & dosage
Dose-Response Relationship, Drug
Male
Myocytes, Cardiac
/ drug effects
Oligopeptides
/ administration & dosage
Proteasome Endopeptidase Complex
/ drug effects
Proteasome Inhibitors
/ administration & dosage
Rabbits
Rats
Rats, Wistar
anthracyclines
bortezomib
cardiotoxicity
carfilzomib
proteasome inhibitors
Journal
Clinical science (London, England : 1979)
ISSN: 1470-8736
Titre abrégé: Clin Sci (Lond)
Pays: England
ID NLM: 7905731
Informations de publication
Date de publication:
30 08 2019
30 08 2019
Historique:
received:
19
02
2019
revised:
26
07
2019
accepted:
12
08
2019
pubmed:
15
8
2019
medline:
6
5
2020
entrez:
15
8
2019
Statut:
epublish
Résumé
Although proteasome inhibitors (PIs) are modern targeted anticancer drugs, they have been associated with a certain risk of cardiotoxicity and heart failure (HF). Recently, PIs have been combined with anthracyclines (ANTs) to further boost their anticancer efficacy. However, this raised concerns regarding cardiac safety, which were further supported by several
Identifiants
pubmed: 31409729
pii: CS20190139
doi: 10.1042/CS20190139
doi:
Substances chimiques
Anthracyclines
0
Antineoplastic Agents
0
Oligopeptides
0
Proteasome Inhibitors
0
Bortezomib
69G8BD63PP
carfilzomib
72X6E3J5AR
Proteasome Endopeptidase Complex
EC 3.4.25.1
Daunorubicin
ZS7284E0ZP
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1827-1844Informations de copyright
© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.